Dr. Cusnir on the Role of Ramucirumab in Gastric Cancer

Mike Cusnir, MD
Published: Wednesday, Feb 05, 2020



Mike Cusnir, MD, co-director of Gastrointestinal Malignancies at Mount Sinai Medical Center, discusses the utilization of ramucirumab (Cyramza) in gastric cancer.

Ramucirumab, according to Cusnir, is one of the more interesting agents in gastric cancer due to an antiangiogenic agent being used in the first- and second-line settings. Data looking at combinations with ramucirumab are emerging and appear promising, according to Cusnir.

The ramucirumab data can be considered in different patient populations, though the agent appears to have the most activity in patients with borderline poor-performance status, concludes Cusnir.
SELECTED
LANGUAGE


Mike Cusnir, MD, co-director of Gastrointestinal Malignancies at Mount Sinai Medical Center, discusses the utilization of ramucirumab (Cyramza) in gastric cancer.

Ramucirumab, according to Cusnir, is one of the more interesting agents in gastric cancer due to an antiangiogenic agent being used in the first- and second-line settings. Data looking at combinations with ramucirumab are emerging and appear promising, according to Cusnir.

The ramucirumab data can be considered in different patient populations, though the agent appears to have the most activity in patients with borderline poor-performance status, concludes Cusnir.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x